» Articles » PMID: 26305875

ITRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors

Overview
Journal PLoS One
Date 2015 Aug 26
PMID 26305875
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Uveal melanoma is the most common malignancy of the adult eye. The overall mortality rate is high because this aggressive cancer often metastasizes before ophthalmic diagnosis. Quantitative proteomic analysis of primary metastasizing and non-metastasizing tumors was pursued for insights into mechanisms and biomarkers of uveal melanoma metastasis.

Methods: Eight metastatic and 7 non-metastatic human primary uveal melanoma tumors were analyzed by LC MS/MS iTRAQ technology with Bruch's membrane/choroid complex from normal postmortem eyes as control tissue. Tryptic peptides from tumor and control proteins were labeled with iTRAQ tags, fractionated by cation exchange chromatography, and analyzed by LC MS/MS. Protein identification utilized the Mascot search engine and the human Uni-Prot/Swiss-Protein database with false discovery ≤ 1%; protein quantitation utilized the Mascot weighted average method. Proteins designated differentially expressed exhibited quantitative differences (p ≤ 0.05, t-test) in a training set of five metastatic and five non-metastatic tumors. Logistic regression models developed from the training set were used to classify the metastatic status of five independent tumors.

Results: Of 1644 proteins identified and quantified in 5 metastatic and 5 non-metastatic tumors, 12 proteins were found uniquely in ≥ 3 metastatic tumors, 28 were found significantly elevated and 30 significantly decreased only in metastatic tumors, and 31 were designated differentially expressed between metastatic and non-metastatic tumors. Logistic regression modeling of differentially expressed collagen alpha-3(VI) and heat shock protein beta-1 allowed correct prediction of metastasis status for each of five independent tumor specimens.

Conclusions: The present data provide new clues to molecular differences in metastatic and non-metastatic uveal melanoma tumors. While sample size is limited and validation required, the results support collagen alpha-3(VI) and heat shock protein beta-1 as candidate biomarkers of uveal melanoma metastasis and establish a quantitative proteomic database for uveal melanoma primary tumors.

Citing Articles

Quantitative proteomic profiling reveals sexual dimorphism in the retina and RPE of C57BL6 mice.

Jang G, Crabb J, Grenell A, Wolk A, Campla C, Luo S Biol Sex Differ. 2024; 15(1):87.

PMID: 39478535 PMC: 11526624. DOI: 10.1186/s13293-024-00645-9.


Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.

Dian Y, Liu Y, Zeng F, Sun Y, Deng G Hum Vaccin Immunother. 2024; 20(1):2374647.

PMID: 39004419 PMC: 11249029. DOI: 10.1080/21645515.2024.2374647.


Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers.

Velez G, Wolf J, Dufour A, Mruthyunjaya P, Mahajan V Invest Ophthalmol Vis Sci. 2023; 64(14):14.

PMID: 37955612 PMC: 10653261. DOI: 10.1167/iovs.64.14.14.


Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.

Montazeri K, Pattanayak V, Sullivan R Drug Des Devel Ther. 2023; 17:333-339.

PMID: 36785760 PMC: 9921510. DOI: 10.2147/DDDT.S368954.


Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma.

Fei X, Xie X, Qin R, Wang A, Meng X, Sun F BMC Cancer. 2022; 22(1):408.

PMID: 35421957 PMC: 9009011. DOI: 10.1186/s12885-022-09499-z.


References
1.
Pardo M, Garcia A, Antrobus R, Blanco M, Dwek R, Zitzmann N . Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum. J Proteome Res. 2007; 6(7):2802-11. DOI: 10.1021/pr070021t. View

2.
Zuidervaart W, Hensbergen P, Wong M, Deelder A, Tensen C, Jager M . Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest Ophthalmol Vis Sci. 2006; 47(3):786-93. DOI: 10.1167/iovs.05-0314. View

3.
Li Z, Adams R, Chourey K, Hurst G, Hettich R, Pan C . Systematic comparison of label-free, metabolic labeling, and isobaric chemical labeling for quantitative proteomics on LTQ Orbitrap Velos. J Proteome Res. 2011; 11(3):1582-90. DOI: 10.1021/pr200748h. View

4.
Yang Y, Spitzer E, Kenney N, Zschiesche W, Li M, Kromminga A . Members of the fatty acid binding protein family are differentiation factors for the mammary gland. J Cell Biol. 1994; 127(4):1097-109. PMC: 2200063. DOI: 10.1083/jcb.127.4.1097. View

5.
Harbour J . Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol. 2009; 148(6):823-9.e1. PMC: 4470132. DOI: 10.1016/j.ajo.2009.07.004. View